AstraZeneca PLC £27.5bn acquisition of Alexion Pharmaceuticals, Inc. under investigation by competition watchdog
The CMA has opened an invitation to comment until 3 June for parties involved. The FTSE 100 pharma giant has received approval in the US, Canada, Brazil, Russia but was still waiting for the green light from the UK, the EU and Japan. The megadeal was announced in December so the Anglo-Swedish group could boost its growing presence in immunology. The deal will see Alexion shareholders paid US$175 for each share, made up of US$60 in cash and 2.1243 American depositary shares (ADSs), which each represent one-half of one ordinary AstraZeneca share. Shares in the firm were flat at 8,111p on Tuesda...